Infant Bacterial Therapeutics
Sweden - StockholmBiotechnology
Focus: Infant Bacterial Therapeutics is a Swedish public biotech focused on developing bacterial therapeutics for premature infant conditions, particularly necrotizing enterocolitis (NEC). The company operates in a specialized niche of pediatric gastroenterology with limited market competition.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Infant Bacterial Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Infant Bacterial Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
IBP-9414
Necrotizing EnterocolitisClinical Trials (1)
NCT02472769IBP-9414 for the Prevention of Necrotizing Enterocolitis
Phase 2Help build intelligence for Infant Bacterial Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.